Podcast
Rheumnow Podcast
Hosted by Dr. Cush · EN
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
45episodes
Episodes
Newest firstAll episodes
Quiz Talk (5.22.2026)
2w ago00:24:42Tap to summarizeDr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.
Transcribe →Infectious Rheumatology (5.15.2026)
3w ago00:30:15Tap to summarizeDr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Transcribe →Influential Rheumatoid Factors(5/8/2026)
4w ago00:22:20Tap to summarizeDr Jack Cush reviews the news and journal reports from last weekon rheumnow.com
Transcribe →Great Lectures; Great Presentations
May 100:27:45Tap to summarizeDr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Transcribe →
DERM on RheumNow (April 2026)
May 100:15:43Tap to summarizeThe Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY 5. Predictors of Calcinosis Cutis in Systemic Sclerosis 6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB 7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N 8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ 9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review 10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis 11. Brepocitinib in Dermatomyositis
Transcribe →Follow the Money (4.23.2026)
Apr 2400:25:58Tap to summarizeDr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Transcribe →Prescribing Lessons (4.17.2026)
Apr 1700:25:05Tap to summarizeDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Transcribe →Top Four and More (4.10.2026)
Apr 1000:25:58Tap to summarizeDr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.
Transcribe →Whats New PsA? (4.3.2026)
Apr 300:20:59Tap to summarizeDr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.
Transcribe →
PsA GRAPPA Domains: Outcomes With a JAKi
Apr 100:18:06Tap to summarizeDr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains. Sponsored by AbbVie Medical Affairs + Health Impact
Transcribe →